![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215570
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209792
https://www.b3cnewswire.com/202008252108/byondis-initiates-phase-i-study-of-adc-vic-trastuzumab-duocarmazine-niraparib-in-her2-expressing-solid-tumors.html
https://www.pharmacompass.com/pdf/news/pomalyst-pomalidomide-capsules-celgene-corporation-v-synthon-1529990446.pdf
https://www.in-pharmatechnologist.com/Headlines/Regulatory-Safety/Synthon-s-generic-version-of-Copaxone-40mg-approved-in-Europe
https://www.biospectrumasia.com/news/34/9547/regulatory-approval-in-europe-granted-for-synthons-glatiramer-acetate.html
http://www.raps.org/Regulatory-Focus/News/2017/05/25/27667/Copaxone-Generics-Who-Will-Win-First-Filer-Exclusivity/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails